The announcement of Biotricity Inc.'s partnership to conduct cardiac screenings for patients with neurological issues is likely to be viewed positively by investors and the market. This expansion into a new area of healthcare services not only broadens the company's offerings but also positions it as a proactive player in addressing comprehensive patient care. The strategic move could lead to increased market reach and potentially higher revenues, thus positively impacting the stock price in the short term.